Evotec SE ADR (EVO)
Official siteHEALTHCARE • DRUG MANUFACTURERS - SPECIALTY & GENERIC • NASDAQ
Market Cap: $561.51M
Last updated: Nov 17, 2026 at 11:05 AM ET
Evotec SE ADR (EVO) Financials: Revenue, Profit and Cash Flow
Evotec SE ADR reported revenue of EUR 757.26M for the fiscal year ended Dec 31, 2025, down 5.0% from the year before. That year, net income was EUR -99.43M with a net margin of -13.1%, operating cash flow was EUR -9.06M and free cash flow was EUR -78.74M. The quarter ended Sep 30, 2026 had revenue of EUR 164.93M and net income of EUR -26.74M.
Revenue and Margins
The operating margin was -17.9% in the fiscal year ended Dec 2025. Over the 9 years to Dec 2025, revenue grew from EUR 164.51M, a compound annual rate of 18.5%.
| Fiscal year | Revenue | Growth | Gross margin | Operating margin | Net margin |
|---|---|---|---|---|---|
| Dec 2025 | 757.26M | -5.0% | 8.3% | -17.9% | -13.1% |
| Dec 2024 | 796.97M | +2.0% | 14.4% | -17.9% | -24.6% |
| Dec 2023 | 781.43M | +4.0% | 22.4% | -13.7% | -10.7% |
| Dec 2022 | 751.45M | +21.6% | 23.2% | 2.8% | -23.4% |
| Dec 2021 | 618.03M | +23.4% | 24.5% | 6.6% | 34.9% |
| Dec 2020 | 500.92M | +12.2% | 25.1% | 9.7% | 1.3% |
| Dec 2019 | 446.44M | +18.9% | 29.8% | 14.0% | 8.5% |
| Dec 2018 | 375.40M | +45.7% | 29.8% | 20.6% | 22.4% |
| Dec 2017 | 257.63M | +56.6% | 32.0% | 14.6% | 9.4% |
| Dec 2016 | 164.51M | N/A | 35.6% | 19.1% | 16.7% |
Income Statement
In the fiscal year ended Dec 2025, the net loss narrowed from the year before. In the quarter ended Sep 2026, the net loss narrowed from the same quarter a year earlier.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 757.26M | 796.97M | 781.43M | 751.45M | 618.03M | 500.92M | 446.44M | 375.40M | 257.63M | 164.51M |
| Cost of revenue | 694.60M | 682.09M | 606.38M | 577.38M | 466.49M | 375.18M | 313.55M | 263.39M | 175.06M | 105.95M |
| Gross profit | 62.66M | 114.88M | 175.05M | 174.06M | 151.54M | 125.74M | 132.89M | 112.02M | 82.57M | 58.55M |
| Research and development | 74.33M | 50.86M | 112.53M | 76.64M | 65.70M | 59.61M | 58.43M | 35.62M | 17.61M | 18.11M |
| Operating income | -135.31M | -142.52M | -107.09M | 20.85M | 41.00M | 48.56M | 62.59M | 77.46M | 37.49M | 31.34M |
| Net income | -99.43M | -196.08M | -83.91M | -175.66M | 215.51M | 6.28M | 38.16M | 84.17M | 24.26M | 27.53M |
| EBITDA | -13.89M | -80.66M | -7.16M | N/A | 316.63M | 90.36M | 86.77M | 105.88M | N/A | 45.57M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 164.93M | 145.85M | 159.22M | 253.27M | 163.89M | 171.24M | 199.98M | 221.23M | 184.89M | 182.12M | 208.73M | 201.31M |
| Gross profit | 19.80M | -1.61M | -1.59M | 78.46M | -62.00K | 8.59M | 27.23M | 46.10M | 18.28M | 15.74M | 34.76M | 37.67M |
| Operating income | -27.11M | -51.97M | -56.35M | 37.21M | -44.50M | -27.77M | -20.01M | 8.13M | -26.49M | -104.61M | -18.21M | -11.55M |
| Net income | -26.74M | -47.42M | -123.94M | 14.62M | -43.09M | -43.48M | -31.58M | -40.84M | -39.63M | -94.93M | -20.67M | -16.13M |
Balance Sheet
As of Dec 2025, total debt of EUR 447.64M exceeded cash and equivalents by 29.31M.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.78B | 1.91B | 2.30B | 2.26B | 2.24B | 1.84B | 1.38B | 771.88M | 667.27M | 351.37M |
| Current assets | 762.62M | 681.96M | 903.16M | 1.07B | 1.10B | 806.13M | 527.05M | 249.77M | 180.25M | 169.24M |
| Cash and equivalents | 418.34M | 306.39M | 510.91M | 400.70M | 699.33M | 517.05M | 310.97M | 109.06M | 67.02M | 83.94M |
| Total liabilities | 964.64M | 959.98M | 1.18B | 1.07B | 857.48M | 951.26M | 844.39M | 347.00M | 335.52M | 137.43M |
| Short-term debt | 103.64M | 50.80M | 149.09M | 16.38M | 50.61M | 36.72M | 23.27M | 56.92M | 168.47M | 21.60M |
| Long-term debt | 344.01M | 392.74M | 307.09M | 328.30M | 326.34M | 331.02M | 324.89M | 54.68M | 20.30M | N/A |
| Shareholder equity | 813.36M | 952.52M | 1.12B | 1.19B | 1.38B | 886.41M | 535.47M | 424.00M | 330.75M | 213.03M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Total assets | 1.50B | 1.57B | 1.64B | 1.71B | 1.77B | 2.12B | 2.10B | 1.91B | 2.22B | 2.14B | 2.39B | 2.25B |
| Total liabilities | 863.31M | 908.40M | 941.17M | 900.24M | 972.56M | 1.13B | 1.12B | 959.98M | 1.14B | 1.06B | 1.19B | 1.13B |
| Cash and equivalents | 299.01M | 348.36M | 388.32M | 401.79M | 174.04M | 314.39M | 308.26M | 293.46M | 258.14M | 237.80M | 462.58M | 510.91M |
| Shareholder equity | 641.66M | 665.58M | 700.35M | 813.70M | 800.14M | 992.83M | 985.29M | 952.52M | 1.08B | 1.08B | 1.20B | 1.12B |
Cash Flow
Operating cash flow was negative in the fiscal year ended Dec 2025.
Annual
| Line item | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -9.06M | 18.22M | 33.95M | 205.81M | 122.24M | 44.72M | 42.22M | 156.24M | 10.83M | 67.36M |
| Capital expenditures | 69.68M | 132.24M | 216.00M | 181.35M | 118.94M | 99.07M | 31.91M | 27.87M | 17.59M | 10.15M |
| Free cash flow | -78.74M | -114.02M | -182.05M | 24.46M | 3.29M | -54.35M | 10.31M | 128.37M | -6.76M | 57.21M |
| Dividends paid | 0 | 0 | 0 | 0 | 0 | N/A | N/A | N/A | 1.72M | 2.02M |
| Investing cash flow | 159.86M | -71.19M | N/A | -412.80M | -243.85M | -155.09M | -86.63M | -39.13M | -269.03M | -5.97M |
| Financing cash flow | -30.93M | -161.42M | 84.82M | -58.15M | 398.43M | 246.41M | 211.26M | -77.76M | 240.72M | -19.67M |
Quarterly
| Line item | Sep 2026 | Jun 2026 | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 | Mar 2024 | Dec 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | -43.91M | -110.23M | -2.18M | 63.63M | -67.56M | 26.56M | -31.81M | 74.22M | 42.60M | -56.51M | -51.22M | 19.94M |
| Capital expenditures | 8.01M | 9.32M | 4.23M | 15.52M | 21.40M | 23.86M | 21.84M | 25.08M | 28.34M | 42.28M | 43.67M | 63.37M |
| Free cash flow | -51.92M | -119.54M | -6.41M | 48.11M | -88.96M | 2.70M | -53.65M | 49.14M | 14.26M | -98.79M | -94.89M | -43.42M |
Frequently Asked Questions About EVO
What is Evotec SE ADR's annual revenue?
Evotec SE ADR reported revenue of EUR 757.26M for the fiscal year ended Dec 31, 2025.
How fast is Evotec SE ADR's revenue growing?
Revenue was down 5.0% for the fiscal year ended Dec 31, 2025 compared with the year before. The compound annual revenue growth rate over 3 years was 0.3%.
Is Evotec SE ADR profitable?
No. Evotec SE ADR reported net income of EUR -99.43M for the fiscal year ended Dec 31, 2025, with a net margin of -13.1%.
How much free cash flow does EVO generate?
For the fiscal year ended Dec 31, 2025, operating cash flow of EUR -9.06M minus capital expenditures of EUR 69.68M produced free cash flow of EUR -78.74M.
How much debt does Evotec SE ADR have?
The balance sheet dated Dec 31, 2025 reported long-term debt of EUR 344.01M, short-term debt of EUR 103.64M and cash and equivalents of EUR 418.34M.
EVO pages: Overview, Financials, Competitors